Item 1.01. Entry into a Material Definitive Agreement.

As previously disclosed in the Current Report on Form 8-K filed by NKGen Biotech, Inc. (the "Company") on September 19, 2023 and September 29, 2023, the Company entered into subscription agreements with certain investors (the "Investors"), pursuant to which the Investors agreed to purchase an aggregate of 8,209,996 warrants at a purchase price of $1.00 per warrant (the "Subscribed Warrants"). Pursuant to the terms of the Subscribed Warrants, Investors had the right to convert one-third of the Subscribed Warrants into shares of the Company's common stock, par value $0.0001 (the "Common Stock"), on a cashless basis after a testing period ending 180 days from the closing of the Company's business combination on September 29, 2023, with the exercise price per share of the remaining Subscribed Warrants resetting to $5.00. On April 25, 2024, the Company amended and restated the Subscribed Warrants, (the "AR Subscribed Warrants"). Among other things, the AR Subscribed Warrants: (i) delay the Investor's right to convert the Subscribed Warrants on a cashless basis and (ii) reset and cap the exercise price to $2.00 per share for all Subscribed Warrants.

As previously disclosed, the Company issued a 12% promissory note in the principal amount of $330,000 and a 12% promissory note in the principal amount of $220,000 (together, the "Notes"), to Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Capital, LLC (collectively, "Meteora") and Sandia Investment Management LP ("Sandia" and together with Meteora, the "Noteholders").

On April 28, 2024, the Company entered into letter agreements with each of Meteora (the "Meteora Letter") and Sandia (the "Sandia Letter" and together with the Meteora Letter, the "Letters") in connection with the Notes. Pursuant to the Notes, the Noteholders, may, in their sole discretion, require the Company to repay all or any portion of the outstanding Principal Amount (as defined in each Note) and interest then due under such Note (the "Repayment Right") upon receipt of cash proceeds in excess of $5 million (such cash proceeds greater than $5 million, the "Excess Proceeds"). Pursuant to the Letters, the Noteholders have agreed not to exercise the Repayment Right with respect to the outstanding Principal Amount and interest until such time as the Excess Proceeds exceed $5 million (a total of $10 million in cash proceeds from the issuance date of each respective Note). In consideration of the Noteholders' entry into the Letters, the Company has agreed to (i) pay cash consideration to each Noteholder, (ii) issued shares of Common Stock to each Noteholder and (iii) issue warrants entitling each Noteholder to purchase shares of Common Stock at an exercise price of $2.00 per share.

The foregoing descriptions of the AR Subscribed Warrants, Meteora Letter and Sandia Letter do not purport to be complete and are qualified in their entirety by the terms and conditions of the AR Subscribed Warrants, Meteora Letter and Sandia Letter, which are filed as Exhibits 4.1, 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.